Biotech Values

[LongRun8]

AGN comes off looking very desperate with this. They're setting the stage to tell providers that they should -- off label and based off a shoddy study -- simply double the current Botox dose to achieve 24-wk effect. It's a win-win situation for AGN -- more toxin purchased and less market share given up to RVNC. The question, though, is if providers would be willing to do this...or if they'd rather just jump ship and use daxi, which will hopefully have a true 24-wk label.